ECONDARY brain damage results from a complex sequence of pathophysiological events that evolve over time and space. 11, 17 After TBI the intracellular influx of the second messenger Ca ϩϩ activates phospholipase A 2 and COXs. The ensuing lipid peroxidation induces cell membrane damage and release of toxic prostanoids and is supported by generation of reactive O 2 species. The reactive O 2 species overwhelm endogenous scavenging mechanisms and inflict downstream injury executed by apoptosis and inflammation. 8, 12, 28 Prostanoids are major contributors to the intrinsic inflammatory CNS response (prostaglandins such as PGE 2 , PGD 2 , PGF 2␣ ; thromboxanes such as thromboxane A 2 ; and prostacyclins such as PGI 2 ). These are synthesized by the enzyme prostaglandin endoperoxide synthase (also known as COX), which is the rate-limiting enzyme. 8, 20 Furthermore, COX has peroxidase activity and can induce formation of O 2 radicals and dopamine quinones independent of its metabolism of arachidonic acid.
a neuropathologically confirmed diagnosis of TBI were included in this study. The survival time post-TBI varied from 1 hour to several months. Brain tissue was obtained from an updated TBI bank (Table  1) reported previously. 3 Tissue specimen procurement was performed according to the ethical guidelines of the University of Tü-bingen. Tissue obtained in patients whose immune status was altered because of immunosuppressive therapy or meningitis and/or encephalitis was excluded from this study. For controls, the results were compared with tissue obtained in corresponding areas of three normal brains described previously. 3, 44 In addition to patient data, hematoxylin and eosin, Luxol fast blue, and iron staining were used for evaluation of the typical histological features defined as standard indications of an injury's age. 11 The mean time before obtaining postmortem samples was 2.5 Ϯ 0.4 days.
Immunohistochemical Studies
After formaldehyde fixation and paraffin embedding, rehydrated 2-m sections were boiled seven times for 5 minutes in citrate buffer (2.1 g sodium citrate/L, pH 6) in a 600-W microwave oven. Endogenous peroxidase was inhibited with 1% H 2 O 2 in methanol (1:10) for 15 minutes. Sections were incubated with 10% normal porcine serum to block nonspecific binding of immunoglobulins. Monospecific polyclonal antibodies directed against COX-1 were diluted 1:400 in 1% BSA/TBS (0.025 M Tris, 0.15 M NaCl) and incubated for 1 hour at room temperature. Specific binding of antibodies was detected with a secondary biotinylated swine anti-rabbit immunoglobulin G Fab 2 antibody fragment (1:400) for 30 minutes, followed by incubation with a peroxidase-conjugated streptavidin-biotin complex. The enzyme was visualized with diaminobenzidine as a chromogen. Sections were counterstained with the Mayer hemalaun stain. Negative controls consisted of sections incubated in the absence of the primary antibody ( Fig. 1A and B) . The specificity of COX-1 antibody was confirmed by selective inhibition of staining after preincubation for 3 hours on ice with 20-fold excess of the COX-1 peptide, whereas adding of COX-2 peptide did not block staining ( Fig. 1C and D) . 44 To identify areas of DAI we used ␤-APP mAbs (1:50) raised against the pre-A4 695 fusion protein.
Double-Labeling Experiments
In double-labeling experiments, we first labeled a cell-type or activation-specific antigen by using the avidin-biotin complex procedure in combination with alkaline phosphatase conjugates. Specific antigens were labeled with mAbs against GFAP (1:100) to detect astrocytes, or against CD68 for microglia/macrophage identification. Activated microglia/macrophages were detected with antibodies directed against human leukocyte antigen-DR, -DP, and -DQ (1:100) or MRP-8 (1:100). 38 The number of perivascular cells in the Virchow-Robin space was determined using mAbs against CD14 (1: 100) to identify both resident perivascular microglia/macrophages and nonresident infiltrating peripheral blood cells. 2 Furthermore, to characterize the cellular proliferative response, we used a PCNA mAb (1:100). In addition, we used mAbs (1:100) against CD31 for * ARDS = adult respiratory distress syndrome; BSF = basal skull fracture; CF = calvarial fracture; CLL = chronic lymphocytic leukemia; EDH = epidural hemorrhage; ICH = intracerebral hemorrhage; ICP = intracranial pressure; MVA = motor vehicle accident; res = resuscitated; SAH = subarachnoid hemorrhage; SDH = subdural hemorrhage; trep = trepanation.
vessel endothelial cell identification and against CD4 to study the potential immune repertoire of these cells. Briefly, slices were deparaffinized, irradiated in a microwave oven for antigen retrieval, and incubated with nonspecific porcine serum as described earlier. Antibodies were added to the slices at a dilution of 1:100 in 1% BSA/ TBS. Visualization was achieved by adding biotinylated secondary antibodies (1:400) for 30 minutes and alkaline phosphatase-conjugated avidin-biotin complex diluted 1:400 in BSA/TBS for 30 minutes. Next, we developed tissue sections with Luxol fast blue salt chromogen-substrate solution, yielding a blue reaction product. Between double-labeling experiments, slices were irradiated in a microwave oven for 5 minutes in citrate buffer, then COX-1 was immunolabeled as described earlier.
Histological Staining for Myelin and Nuclei
Serial tissue sections adjacent to those used for immunohistochemical studies were stained for myelin by using Luxol fast blue to identify the area of tissue that was obviously damaged or lacked myelin. Nuclei were stained with 0.1% cresyl violet to identify intact compared with damaged areas.
Evaluation and Statistical Analysis and Methodology
The COX-1 ϩ cells from the core of traumatic brain lesions were analyzed, including adjacent reactive perilesional tissue (border zones) or remote areas of the same tissue section (Ͼ 1. ϩ microglia/macrophages (brown, arrowheads) formed clusters in the Virchow-Robin space during the leukocyte infiltration period (blue; CD31 immunoreactivity indicates vessel endothelium). E: During the leukocyte infiltration period, a number of COX-1 ϩ microglia/macrophages were frequently observed being intermingled within the intima and/or vessel wall leaving the vessel lumen (arrowheads). F: In some cases, perikarya and processes of large neurons also expressed COX-1 in injured and normal brains. G: Double-labeling experiments identified the majority of COX-1 ϩ cells (brown) located at the lesion site as CD68 ϩ microglia/macrophages (blue) (arrowheads). H: No COX-1 ϩ cells were observed to coexpress GFAP (astrocytic) antigens. Bar = 100 m.
counted and considered positive if a minimum of two COX-1 ϩ cells were present. The vessels revealing COX-1 ϩ endothelial and/or smooth-muscle cells were analyzed in the same fashion, and data were given in the same way.
Sources of Supplies and Equipment
The porcine serum was acquired from Biochrom, Berlin, Germany. The monospecific polyclonal antibodies were purchased from Santa Cruz Biotechnology, Santa Cruz, CA, as were the COX-1 and COX-2 control peptides, and the mAbs against CD14. The swine anti-rabbit immunoglobulin G Fab 2 antibody fragment was obtained from DAKO, Hamburg, Germany, as was the peroxidase-conjugated streptavidin-biotin complex. The diaminobenzidine was supplied by Fluka, Neu-Ulm, Germany. The ␤-APP A4 mAbs and the GFAP were acquired from Boehringer Mannheim, Mannheim, Germany. The mAbs against CD68 and antibodies against human leukocyte antigens DR, DP, and DQ (MHC class II antibodies) were obtained from Dako, Glostrup, Denmark. This company also supplied the PCNA and mAbs against CD31 and CD4. The MRP-8 mAb (S100A8, 8-5C2) was purchased from BMA, Augst, Switzerland.
Results
Tissue obtained in the brains of 31 patients with TBI and three control brains were evaluated for COX-1 expression by using immunohistochemical studies.
Neuropathologically Unaltered Control Brains
In control brains with no neuropathological alterations, COX-1 immunoreactivity was detected in some microglia/ macrophages (Fig. 1A) . These accounted for 2 to 5% of all cells and were evenly distributed throughout the CNS tissue (MLC 3 Ϯ 0). Only single cells were detected in perivascular spaces (MLS 7 Ϯ 7%), and only rare COX-1 ϩ cells coexpressed the activation-associated MHC class II antigens. Furthermore, single neurons (Ͻ 5%) and few endothelial cells (Ͻ 1%) were labeled.
Traumatic Brain Injury
We analyzed whether the number and distribution of COX-1 ϩ cells was altered after TBI. Injured CNS tissue spared at the lesion core was approximately 1 to 5% of the total cross-sectional area of the brain. We observed lesion-associated COX-1 expression localized to endothelial cells, smooth-muscle cells, and microglia/macrophages. The COX-1 ϩ microglia/macrophages accumulated in injured tissue of the lesion core and in developing bordering perilesional areas, respectively, and formed perivascular clusters in the Virchow-Robin space (Fig. 2 upper left, upper center, lower left, and lower center) .
After analyzing the data with the Student t-test, we detected a significantly higher number (p Ͻ 0.0001) of COX-1-expressing microglia/macrophages at the lesion site (MLC 44 Ϯ 0.7; Fig. 1B ) compared with numbers in remote areas (MLC 15 Ϯ 0.3) or cortical control brain tissue (MLC 5 Ϯ 0.6; Fig. 2 upper left) . In these areas of both primary and delayed secondary injury, the numbers of COX-1 ϩ microglia/macrophages had already increased less than 6 hours postinjury (p Ͻ 0.0001, MLC 33 Ϯ 0.8), at the 1st day (Ͻ 23 hours, MLC 48 Ϯ 1), and 4 to 8 days postinjury (MLC 50 Ϯ 1.6), reaching maximum levels at several weeks after TBI (MLC 58 Ϯ 1.3; Fig. 2 lower left) . Subsequently, the numbers of COX-1 ϩ cells remained elevated for up to several months following TBI (MLC 48 Ϯ 1.1), with the longest survival time being 5 years (60 months). Therefore, accumulation of COX-1 ϩ microglia/macrophages occurred early after traumatic BBB disruption (Ͻ 6 hours) and cell numbers remained elevated for at least several months, in addition to the period of microglia/macrophage activation occurring at Days 3 to 5. 16, 48 In remote areas more than 1.5 cm distant from the lesion core demarcation, COX-1 ϩ cell numbers increased also, although to a lesser degree (Fig. 2 upper left and lower left) . The COX-1 ϩ microglia/macrophages were characterized by morphological hallmarks of both ramified and amoeboid microglia. Activated COX-1 ϩ microglial phenotypes were confined to the lesion core and adjacent reactive tissue (border zones, Fig. 1B) , whereas remote from the lesion site we also identified a few COX-1 ϩ microglial phenotypes with fine elongations. Amoeboid cells prevailed during the first 2 weeks after TBI. With aging of the lesions, a few parenchymal ramified COX-1 ϩ cells were also observed. Another significant population of COX-1 ϩ microglia/macrophages, observable from Days 4 to 8, had cytoplasmic vacuoles and large round nuclei, which are morphological hallmarks of phagocytic, lipid-loaded, foamy macrophages (Fig. 1C) . These COX-1 ϩ cells persisted in the necrotic lesion core and represented the majority of COX-1 ϩ cells in the late phases, that is, from weeks to months post-TBI.
To correlate the expression pattern of COX-1 with different qualitative entities of TBI, we investigated its expression in distinct areas of brain injury. We analyzed areas of predominantly DAI in which there were no hemorrhages by using ␤-APP immunohistochemical studies, and compared these findings with those in areas of primarily hemorrhagic injury. In areas of predominantly DAI (1 hour and 3 and 4 days after axonal injury) we observed a delayed accumulation of COX-1 ϩ microglia/macrophages from Day 3 forward, whereas in hemorrhagic regions early accumulation was evident.
After human TBI, increase in perivascular COX-1 ϩ cell numbers (Fig. 1D) were also observed in the VirchowRobin space (p Ͻ 0.0001, MLS 32% Ϯ 7%), compared with control brains (MLS 7 Ϯ 7%; Figs. 1E and 2 upper center). These perivascular areas represent the major infiltration routes for extravasating cells into the CNS. Early (Ͻ 6 hours) after traumatic BBB disruption, pronounced areas of the Virchow-Robin space (MLS 26 Ϯ 6%) contained COX-1 ϩ microglia/macrophages ( Fig. 2 lower center) . During this time period a number of COX-1 ϩ monocytes were frequently observed intermingled within the intima and vessel wall leaving the vessel lumen (Fig. 1E) . Numbers of COX-1 ϩ cells in perivascular spaces increased further during Day 1 (MLS 37 Ϯ 6%) reaching maximum levels from Days 4 to 8 (MLS 53 Ϯ 13%), when more than half of the counted vessels were surrounded by COX-1 ϩ cells. Cell numbers then declined during the ensuing weeks and months after TBI. Profound accumulation of lesion-associated COX-1 ϩ cells in the perivascular Virchow-Robin space paralleled the leukocyte infiltration period. 16, 17, 48 Also at the site of the lesion, the numbers of COX-1 ϩ vessels, which are characterized by immunopositive endothelial and/or smooth-muscle cells, increased after TBI (MLV 44.2 Ϯ 4%) compared with control brains (MLV 13.3 Ϯ 3%; Fig. 2 upper right) . More precisely, the numbers of COX-1 ϩ vessels (Fig. 2 lower right) hours postinjury (MLV 40 Ϯ 8.2%), reaching the first maximum during the 1st day (MLV 62 Ϯ 4%), followed by a decrease until 2.5 days postinjury and reaching a second maximum at 4 to 8 days (MLV 55 Ϯ 13%). Subsequently, the number of COX-1 ϩ vessels decreased, but remained above control levels. In general, upregulation of COX-1 protein expression, demonstrated by the accumulation of COX-1 ϩ cells, such as parenchymal microglia/macrophages, was evident for up to several months after TBI, compared with control brains (p Ͻ 0.0001; Fig. 2 lower left) . The COX-1 expression by monocytic cells in perivascular spaces and by vessels (endothelial and smooth-muscle cells) reached transient maximum levels correlating with the leukocyte infiltration period and the BBB breakdown. After this period, the numbers of COX-1-expressing cells in perivascular spaces and in vessels (endothelial and smooth-muscle cells) were still enhanced, compared with those found in normal brains (Fig. 2 lower center and lower  right) . In some cases, perikarya and processes of large neurons expressed COX-1 in normal and injured brains, and this expression was not restricted to lesional or perilesional areas (Fig. 1F) .
Double-Labeling Experiments
To characterize the cellular origin of COX-1 expression, we performed double-labeling experiments. Furthermore, neurons were distinguished from nonneuronal cells by nuclear size, shape, and the presence of a nucleolus (Fig. 1F) . The majority of COX-1 ϩ cells located in the lesion core coexpressed the CD68 antigen (Ͼ 80%; Fig. 1G ). The COX-1 ϩ cells frequently coexpress MHC class II antigens or the monocytic activation antigen MRP-8 (50-80%). This Ca ϩϩ binding protein, which specifically binds to arachidonic acid, 22 is closely associated with microglia activation. The COX-1 ϩ cells coexpressing the CD68 antigen were mostly observed in territories of phagocytic activity, such as the pannecrotic lesion core, indicating a predominantly phagocytic immunophenotype. In contrast, coexpression with MHC class II and MRP-8 was not restricted to areas of phagocytic activity. Occasionally, COX-1 ϩ cells coexpressed CD4 molecules (10-30%), and frequently, COX-1 ϩ cells coexpressed PCNA (50-60%). These proliferating cells were mostly confined to the lesion core. No COX-1 ϩ cells were identified that coexpressed pan-T-lymphocytic (CD3), pan-B-lymphocytic (CD20), or astrocytic (GFAP) antigens (Fig. 1H) .
Discussion
In this study we have analyzed COX-1 expression in 31 traumatically injured brains and compared them with neuropathologically unaltered control brains. We observed a significant, persistent accumulation of COX-1 To date, the counterpart to COX-1, the highly inducible COX-2, has been associated with diverse pathological conditions in nonneuronal (that is, kidney and joint cartilage) and neuronal tissue. 36 In the CNS, COX-2 expression was confined to inflammatory, 34, 47, 50 neoplastic, 6, 7, 49 degenerative, 54 traumatic, 17, 39 and ischemic 18, 34, 35, 42 disorders. Therefore, in recent studies of CNS injury attention has been focused on the COX-2 isoform, which is expressed by vulnerable neurons, endothelial cells, and astrocytes. 18, 34, 35, 41, 53 Nevertheless, the idea of a unique role for COX-2 as the only responsible, inducible inflammatory mediator is complicated 10, 53 and has been questioned. 24, 32 The expression of the late-inducible, differentiation-associated COX-1 isoform, which is associated with tissue homeostasis, as the source of physiologically important prostaglandins did not gain much attention, although it led to identical proinflammatory and injury-producing products. We know that COX-1 is involved in the physiological response, constituting the regulation of blood homeostasis (vasoconstriction, platelet aggregation, angiogenesis, and blood pressure) 5, 47, 50 and differentiation of neuronal, 19 stem, 45 and monocytic cells. 14 Only scarce data on the pathophysiological role of COX-1 are available. The expression of COX-1 induced tumorigenic transformation in immortalized endothelial cells and altered the properties related to multiple drug resistance, resulting in reduced chemotoxicity in C6 glioblastoma cells. 41 Disease-associated accumulation of COX-1 ϩ microglia was evident in amyloid plaques of AD, indicating a disease-related, localized increase of COX-1. 55 Likewise, little is known about the elments involved in regulating COX-1 gene expression; COX-1 is a delayed response gene, 19 and its transcription is inducible by basic fibroblast growth factor, by epidermal growth factor in mouse myeloblastoma (MC3T3), and by nerve growth factor in neurogenic rat pheochromocytoma cells (PC12), which are used as a model to study neurite outgrowth. 35 In addition, there have been reports of induction of COX-1 during differentiation of monocytes initiated by phorbol ester.
14 Surprisingly, reactive microglia, which are sensors for pathological events in the CNS 23 and are essential to tissue remodeling and one of the major sources of prostaglandins in this system, 27, 31 are not the main source of the pathogen-associated COX-2 expression. 18, 42 The role of microglia in lipid oxygenation is supported, however, by their capacity to produce PLA2, COX-1, and the vasoactive PGE 2 and thromboxane A. 27, 31, 43 This supports a distinct regulation of COX-1 and COX-2 in the brain and peripheral organs, which might relate to the organ-specific differences in the use of arachidonic acid as a substrate. 46 Because COX activity is important after CNS injury, 8, 9, 34, 35, 42 we defined COX-1 expression following human TBI. It appeared that COX-1 was expressed constitutively only by a few microglia/macrophages, some endothelial cells, and rare neurons. There were significant accumulations of COX-1 ϩ microglia/macrophages at the lesion core and in adjacent perilesional areas. These results indicate a paracrine role of COX-1 metabolites in the modification of the posttraumatic microenvironment. Because it exerted the same enzymatic activity as COX-2, our data implicate a role of COX-1 in the monocyte and macrophage-mediated secondary (bystander) damage during lipid hydrolysis, damage that is induced by converting the membrane phospholipid product, arachidonic acid. The COX-1 converts arachidonic acid into PGG 2 (bisoxygenase activity), and further into PGH 2 (peroxygenase activity), and gives rise to subsequently metabolized free radical reactive O 2 species. 31 The activity of COX-1 might also be implicated in other secondary injury mechanisms such as edema initiated by progressive endothelial damage and vasogenic dysfunction. 43 This theory is supported by the bimodal accumulation of COX-1 ϩ in vessels confined to the lesion, culminating during the 1st day and from Days 4 to 8, a crucial period of edema formation, 11 which also occurs in rat and human posttraumatic pathophysiological events in a biphasic mode. 15, 16 Our data demonstrate both the early presence of COX-1 ϩ cell accumulation in the Virchow-Robin space (the major infiltration route for extravasating cells into the CNS), 48 paralleling the leukocyte infiltration period, 11, 16 and the persistence of COX-1 ϩ cells in damaged tissue areas. Our results indicate a substantial proinflammatory contribution of extravasating and engrafting 21 peripheral COX-1 ϩ bloodderived cells. These newly acquired constituents form a long-term, potential substrate for intervention.
In addition, persistent COX-1 ϩ cell accumulation might represent an assessable residual inflammatory risk factor linking the enhanced incidence and prevalence of AD to patients who suffer head trauma. 29, 33, 37 We emphasize this because, first, head injury is an important risk factor for the development of AD; second, inflammation mediated by proinflammatory entities stimulates the production of ␤-APP; 4 and, third, these inflammatory mediators were detected intracerebrally after injury. Because inflammatory mechanisms, including expression of COX-1, 54 are considered to be involved in the pathogenesis of AD, 1,4 injured patients might wish to receive long-term nonsteroidal antiinflammatory drug treatment after suffering brain trauma. Based on experimental 25, 52 and clinical data, 30, 40 nonselective COX blocking, including blocking of COX-1, might delay the onset of disease or decrease the incidence of AD within this patient group. Thus, we have identified COX-1 as a potential substrate for nonsteroidal antiinflammatory drug action in the human brain after TBI.
Conclusions
Several lines of evidence implicate a pathophysiological role of posttraumatic COX-1 expression by activated microglia/macrophages. Activated microglia/macrophages are known to promote angiogenesis 31 and regeneration, 15, 43 but also to generate toxic agents. 21 These results indicate that a local increase in COX activity can be caused by both transient local upregulation of COX-2 expression and by the persistent accumulation of infiltrating COX-1-expressing inflammatory cells. These findings substantially challenge current paradigms of a selective role of COX-2 in posttraumatic CNS injury response. Thus, therapeutic approaches based on long-term blocking, including blocking of COX-1, might be superior to selective COX-2 blocking to suppress local synthesis of prostanoids.
